Pacific Biosciences of California (PACB) Stock Price, News & Analysis

Company Overview

Pacific Biosciences of California, Inc. (NASDAQ:PACB), commonly known as PacBio, is a biotechnology company specializing in high-resolution, single-molecule real-time (SMRT) DNA sequencing solutions. Founded in 2004 and headquartered in Menlo Park, California, PacBio has developed next-generation sequencing technologies that enable researchers to generate long, accurate reads for comprehensive genomic analysis. Its platforms are designed to deliver insights into complex regions of the genome that are difficult to resolve with short-read sequencing methods.

The company’s flagship products include the Sequel II and Revio Systems, which leverage SMRT Sequencing chemistry and zero-mode waveguide (ZMW) technology to produce highly accurate long reads. PacBio offers a suite of reagents, library preparation kits and software tools—such as SMRT Link—for data management and analysis. These integrated solutions support applications in de novo genome assembly, structural variant detection, full-length transcript sequencing and epigenetic profiling.

PacBio serves a diverse global customer base encompassing academic institutions, pharmaceutical and biotechnology companies, agricultural and environmental research organizations, and government laboratories. Its sequencing platforms are deployed across North America, Europe, Asia-Pacific and other regions, with strategic partnerships aimed at expanding access to advanced genomics in both research and clinical settings. The company’s technologies have been instrumental in projects ranging from human genome reference improvement to agricultural trait discovery and infectious disease surveillance.

Led by Chief Executive Officer Christian Henry and a seasoned management team drawn from the life sciences and technology sectors, PacBio remains committed to advancing genomic science through ongoing investment in research and development. The company continues to enhance throughput, accuracy and ease of use in its sequencing systems, positioning itself at the forefront of precision medicine, agricultural genomics and biological discovery worldwide.

Key Stats

• Today's Range: $1.45 to $1.53
• 50-Day Range: $0.91 to $1.58
• 52-Week Range: $0.85 to $2.72
• Volume: 7.69 million shs
• Average Volume: 9.85 million shs
• Market Capitalization: $450.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.06
• Consensus Rating: Hold

Pacific Biosciences of California Stock Analysis - MarketRank™

Pacific Biosciences of California scored higher than 51% of companies evaluated by MarketBeat, and ranked 542nd out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Pacific Biosciences of California has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 4 buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Pacific Biosciences of California has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Pacific Biosciences of California are expected to grow in the coming year, from ($0.72) to ($0.59) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pacific Biosciences of California is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pacific Biosciences of California is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pacific Biosciences of California has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

13.55% of the float of Pacific Biosciences of California has been sold short.

Short Interest Ratio / Days to Cover

Pacific Biosciences of California has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in Pacific Biosciences of California has recently decreased by 23.80%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pacific Biosciences of California does not currently pay a dividend.

Dividend Growth

Pacific Biosciences of California does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

13.55% of the float of Pacific Biosciences of California has been sold short.

Short Interest Ratio / Days to Cover

Pacific Biosciences of California has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in Pacific Biosciences of California has recently decreased by 23.80%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.91

News Sentiment

Pacific Biosciences of California has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Pacific Biosciences of California this week, compared to 4 articles on an average week.

Search Interest

14 people have searched for PACB on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Pacific Biosciences of California to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pacific Biosciences of California insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.50% of the stock of Pacific Biosciences of California is held by insiders.

PACB Stock Analysis - Frequently Asked Questions

How have PACB shares performed this year?

Pacific Biosciences of California's stock was trading at $1.83 at the start of the year. Since then, PACB shares have decreased by 18.0% and is now trading at $1.50.

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California, Inc. (NASDAQ:PACB) announced its quarterly earnings results on Thursday, May, 8th. The biotechnology company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.04. The biotechnology company had revenue of $37.15 million for the quarter, compared to analyst estimates of $36.90 million. Pacific Biosciences of California had a negative net margin of 430.93% and a negative trailing twelve-month return on equity of 52.07%.
Read the conference call transcript.

Does Pacific Biosciences of California have any subsidiaries?

The following companies are subsidiaries of Pacific Biosciences of California: Circulomics, Omniome, PacBio Singapore PTE Limited, Pacific Biosciences Canada Limited, Pacific Biosciences Germany GmbH, Pacific Biosciences Japan GK, Pacific Biosciences (Shanghai) Co. Ltd., Pacific Biosciences UK Limited, and Pacific Biosciences International LLC.

Who are Pacific Biosciences of California's major shareholders?

Top institutional shareholders of Pacific Biosciences of California include Mirador Capital Partners LP (0.19%) and Wealth Enhancement Advisory Services LLC (0.01%). Insiders that own company stock include Oene Mark Van, Christian O Henry, Jeff Eidel, Susan G Kim, Michele Farmer and William W Ericson.
View institutional ownership trends.

How do I buy shares of Pacific Biosciences of California?

Shares of PACB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Pacific Biosciences of California own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pacific Biosciences of California investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Alphabet (GOOG).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/10/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:PACB
• CIK: 1299130
• Web: www.pacb.com
• Phone: (650) 521-8000
• Fax: 302-636-5454
• Employees: 730
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Pacific Biosciences of California: $2.06
• High Price Target: $3.50
• Low Price Target: $1.25
• Potential Upside/Downside: +37.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.44
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$309.85 million
• Net Margins: -430.93%
• Pretax Margin: -431.71%
• Return on Equity: -52.07%
• Return on Assets: -15.82%

Debt

• Debt-to-Equity Ratio: 7.05
• Current Ratio: 6.68
• Quick Ratio: 5.87

Sales & Book Value

• Annual Sales: $152.36 million
• Price / Sales: 2.95
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.85 per share
• Price / Book: 0.81

Miscellaneous

• Outstanding Shares: 300,085,000
• Free Float: 292,583,000
• Market Cap: $450.13 million
• Optionable: Optionable
• Beta: 2.16